Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CytoDyn Submits Protocol for Phase 2b Trial for Treatment Naïve HIV Patients
http://finance.yahoo.com/news/cytodyn-submits-protocol-phase-2b-103000278.html
I guess I can't argue you with you on that
Well after all that SA author is pro Gilead so anything that has the potential to eat into its market share he will not praise. As for the company not being bought out it's like you said it is not one sided. Both parties have to come to an agreement. Plus we are not behind the scenes so we don't know if Gilead has made albeit a small offer or not. Maybe CYDY management wants more than what Gilead has to offer. Maybe Gilead only wants to pay $500 mil to the buy the company? Nobody knows because we are not on the inside. But the data to date and the patients with reduced viral loads speak for themselves. I know what the company is worth and IMO management taking anything less than $1B or $2B would be shameful.
yes i see possible approval from both phase 3 trials around 2nd half 2017 as well.
I hope RXII has some news soon, its been 2 months since the last PR.
What? Are you crazy? Did you even listen to the CC? They are going to be able to tone down recruitment of the trials from 300 patients to 150 patients. That would decrease recruitment time by 5 to 6 months, which means results out sooner.......lmao at your comment.
Let me tell you why AMBS will never work. "Nepotism"
Nepotism is hiring a family member over someone else that would be more qualified for the job.
It's obvious that Gerald C is not qualified to run a biotechnology company. The only reason why he was hired is because his father is the head of the BOD. Which is a death knell, because it is also the reason why he will never be fired. His father who is on the BOD will never fire his own son. That's why this company has been doomed to begin with.
That's bad news for Gilead, because now if it wants to buy CYCY it has to offer a substantial value like 200% to 300% premium.
Actually monocolonal antibodies are sought out after. They are #1 on the list of big pharma because they work, and they have less side effects than other drugs.
Best news ever. That would bring down clinical trial timeframe by 6 to 7 months. That means results should be out earlier than expected. Awesome news by CYDY.
What? That tweet made no sense. Yes they don't have to pay salary for a CFO, but how are they going to weed out the financials without a Chief Financial officer? They are the ones responsible for the money side of the business. The CEO is crazy
5 years? Son, they are releasing phase 3 data in 2017. That should put approval in 20017 or early 2018. That's like 2 years
You pretty much nailed it sir. That's exactly what's happening
It's not bad news buddy, They are just holding the conference call as an update to the shareholder meeting that is coming up in August. To vote for authorized shares and possible r/s if they need to implement it. It is not gonna be good or bad news. Just general corporate purpose news with proxy.
WHen they say authorized shares it is not immediate dilution. Its for when they need additional money so it could be 3 to 6 months from now. They just need them authorized so they don't have to wait for a meeting to do so.
Yah but not for a product in phase 3. I can see a biotech that uplists to a higher exchange with a phase 2 struggling. Most that I have seen in phase 2 have not done so well. But CYDY is in a unique situation because they are already in phase 3.
While it may seem like a long wait, I estimate that results for one of the HIV trials should be done by June/July of 2017. That's one year from now which is doable. Could take a few more months longer depending upon enrollment though.
I bought around there too, and yes it's a good price. They will need to uplist soon.
Company has been quiet almost two months with no PR, I hope this means that they are keeping a low profile because of a deal.
Anyone else taking advantage of this price. I'm gonna do one more big buy before August 31, 2016 just in case they enact the r/s. IMO they will have to otherwise I don't see how this will trade higher organically before then.
Well sorry I meant to say higher than 700k for all. But still a hefty $230,000 a year for doing nothing for GC. Everyone else on the board gets paid as well.
http://finance.yahoo.com/q/pr?s=AMBS+Profile
But remember that says as of 2015. By now they could be getting paid more.
Not much in the way of news really other than a potential partnership or funding. Trials will probably complete by May/June of 2017 maybe earlier depending upon enrollment. Just have to be patient in these types of biotechs. The good news is that CYDY is already in phase 3. I'm in other biotechs where they are only at phase 2 in multiple trials.
He doesn't care as long as he is earning his yearly salary of $600k
correct right now it is one injection per week, but the company said it has future plans to get it so it can be dosed once a month instead. Although, that's probably farther out after this initial phase 3 testing.
Happy Independence day to you as well sir. I'm vested in CYDY for the long-term I did some more research and found Truvada, one of gilead's HIV drugs, which has so many toxic side effects. You wonder how it ever got approved in the first place.
TRUVADA can cause serious side effects:
Too much lactic acid in your blood (lactic acidosis), which is a serious medical emergency. Symptoms of lactic acidosis include weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, nausea, vomiting, stomach-area pain, cold or blue hands and feet, feeling dizzy or lightheaded, and/or fast or abnormal heartbeats.
Serious liver problems. Your liver may become large and tender, and you may develop fat in your liver. Symptoms of liver problems include your skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, and/or stomach-area pain.
You may be more likely to get lactic acidosis or serious liver problems if you are female, very overweight (obese), or have been taking TRUVADA for a long time. In some cases, these serious conditions have led to death. Call your healthcare provider right away if you have any symptoms of these conditions.
Worsening of hepatitis B (HBV) infection. If you also have HBV and take TRUVADA, your hepatitis may become worse if you stop taking TRUVADA. Do not stop taking TRUVADA without first talking to your healthcare provider. If your healthcare provider tells you to stop taking TRUVADA, they will need to watch you closely for several months to monitor your health. TRUVADA is not approved for the treatment of HBV.
Serious side effects of TRUVADA may also include:
Kidney problems, including kidney failure. Your healthcare provider may do blood tests to check your kidneys before and during treatment with TRUVADA. If you develop kidney problems, your healthcare provider may tell you to take TRUVADA less often, or to stop taking TRUVADA.
Bone problems, including bone pain or bones getting soft or thin, which may lead to fractures. Your healthcare provider may do tests to check your bones.
Changes in body fat, which can happen in people taking HIV-1 medicines.
Changes in your immune system. If you have HIV-1 infection and start taking HIV-1 medicines, your immune system may get stronger and begin to fight infections. This may cause minor symptoms such as fever, but can also lead to serious problems. Tell your healthcare provider if you have any new symptoms after you start taking TRUVADA.
The most common side effects in people taking TRUVADA to treat HIV-1 infection include: diarrhea, nausea, tiredness, headache, dizziness, depression, problems sleeping, abnormal dreams, and rash.
Common side effects in people taking TRUVADA to reduce the risk of getting HIV-1 infection include: stomach-area (abdomen) pain, headache, and decreased weight.
Just to name a few..........
meanwhile Pro 140 has no side effects with an excellent safety profile and only needs to be administered once a week. While patients taking Truvada have to take it every day and causes all those side effects.
Buying more shares On monday CYDY, moved up my limit buy order to $1.11 lets see if that holds and heads higher!
I had a bid in the morning before the open on a limit order to buy thousands of shares CYDY and only 825 filled the rest never filled and the stock bounced higher. Seems there is good buy support around $1.05 , $1.06 in that area.
Exactly even if they don't get the share price organically, they may have to implement the reverse split. That won't be a bad thing though because getting on the NASDAQ or NYSE means institutions can start to buy shares.
CYDY is in a unique place because most other OTC biotechs that I have seen uplist are only in the phase 2 stage of clinical testing. CYDY already has two phase 3 trial it will run.
Why so long for a 10 patient study? 2020? That's like 4 years from now? That means that a phase 3 trial, if the phase 2 is successful, won't start until 2021 and end around 2025. Well Hopefully the company will still exist by then hah. No position for me in this ... thank god
True, but hostile is last resort option. Most big pharma approach management first with a letter, or talk with them. Then if they need to go hostile they will. They don't go hostile immediately until all other options are exhausted first.
No, first they have to talk to management. If management feels the offer is adequate and they agree to sell, then they take it to the shareholders. It doesn't go to the shareholders directly first.
First management has to agree that the offer is substantial enough, then they can take it to the shareholders. If management doesn't like the offer they don't make mention of it then because they don't agree with the offer.
Cytodyn management must first agree among themselves that the offer is worth it, then its taken to shareholders for a vote.
Yes I agree with you!
It depends if they can get a partner beforehand. If not they will have to dilute, but if they can strike a deal with big pharma they won't need to.
I agree with you on that sentiment. Plus big pharma have the cash. About 2 to 3 years ago Roche bought Intermune for their pulmonary fibrosis drug and paid $8.5 billion if I recall correctly. I will have to look that up again. But anyways you are right even a 20+bagger is golden for investors here.
yah 2% is not a lot of short interest. If you look at stocks with large short interest it might be around 15% or 30%. Those are large short interest percentages. 2% short interest is not much
And the only reason why it tanked was because phase 2b data was torn apart by Adam F and other short sellers. After that it tanked down from $11 to $5. Although, I don't see that happening with CYDY, mainly because it already has good results shown in phase 2b and because phase 3 data won't be out until late 2017.
Because the CEO has said in many interviews that they are in talks but can't talk about it to the public. When CEO's say that it means they are in talks.
Oh I found it by the way its not set at exactly for 1 for 8 reverse split read the line from the annual report:
"Approval of a reverse stock split at a ratio of any whole number between one-for-two and one-for eight,
as determined by our board of directors, at any time before August 27, 2016, if and as
determined by our board of directors;."
That means it hasn't yet been determined it can be anywhere between 1 for 2 up to 1 for 8.
Source: http://www.envisionreports.com/CYDY/2015/0D117JN15F/Documents%5CCytoDyn__Proxy_Statement_07-22-15__Print-Ready__final_07-16-15.pdf
Where 1 for 8? its set already as a 1 to 8 r/s in August or has yet to be determined? That doesn't make sense that would put the share price at $9.04 at current price. That's a little too much they don't need that big of a reverse split, that would also put the float to 14 million shares outstanding
Well probably nobody wants to short it anymore, especially after Rxi announced a potential merger agreement. I have to give two thumbs up to management for at least putting this PR out the share price has swung from $1.40 per share all the way to $2.90 per share where it is now. That one strategic aquisition PR is what pretty much helped the stock recover. Otherwise it would have been shorted further.
So the phase 2b monotherapy data came but the stock price didn't act accordingly. I get that management tried to boost the share price organically but that didn't work. Maybe it's time for management to think about doing a reverse split whatever they need 1 for 2 or 1 for 4 to get to a bigger exchange. It's clear that the OTC is limiting its ability. I believe many have said that management have up until August to do a r/s with the shareholder vote? Maybe it's time CYDY management went ahead and did one anyways. The company on the OTC is going nowhere as institutions can't invest at all.